AR074504A1 - Nucleotidos uracil ciclopropilicos - Google Patents

Nucleotidos uracil ciclopropilicos

Info

Publication number
AR074504A1
AR074504A1 ARP090104736A ARP090104736A AR074504A1 AR 074504 A1 AR074504 A1 AR 074504A1 AR P090104736 A ARP090104736 A AR P090104736A AR P090104736 A ARP090104736 A AR P090104736A AR 074504 A1 AR074504 A1 AR 074504A1
Authority
AR
Argentina
Prior art keywords
alkyl
benzyl
phenyl
hydrogen
formula
Prior art date
Application number
ARP090104736A
Other languages
English (en)
Original Assignee
Medivir Ab
Centocor Ortho Biotech Products L P
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medivir Ab, Centocor Ortho Biotech Products L P filed Critical Medivir Ab
Publication of AR074504A1 publication Critical patent/AR074504A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • C07H19/10—Pyrimidine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • AIDS & HIV (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Compuestos, o una sal o solvato de los mismos, y formulaciones farmacéuticas y el uso de compuestos de fórmula (1) como inhibidores de HCV. Reivindicación 1: Un compuesto de fórmula 1 que incluye cualquier estereoisómero posible del mismo, donde R1 es hidrógeno o halo; R4 es un éster de monofosfato, difosfato o trifosfato, o R4 es un grupo de fórmula (2); R7 es fenilo, opcionalmente sustituido con 1, 2, o con 3 sustituyentes, cada uno seleccionado independientemente entre halo, alquilo C1-6, alquenilo C3-6, alcoxi C1-6, alcoxicarbonilo C1-6, hidroxi, y amino; o R7 es naftilo; o R7 es indolilo o N-alquiloxi C1-6 carbonilindolilo; R8 es hidrógeno, alquilo C1-6, bencilo; R8' es hidrógeno, alquilo C1-6, bencilo; R8 y R8' conjuntamente con el átomo de carbono al cual están unidos forman cicloalquilo C3-7; R9 es alquilo C1-10, cicloalquilo C3-7, bencilo, o fenilo, donde el fenilo puede estar opcionalmente sustituido con 1, 2 o 3 sustituyentes cada uno independientemente seleccionado entre hidroxi, alcoxi C1-6, amino, mono- y dialquilamino C1-6; o una sal o solvato farmacéuticamente aceptable del mismo.
ARP090104736A 2008-12-08 2009-12-07 Nucleotidos uracil ciclopropilicos AR074504A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP08171006 2008-12-08

Publications (1)

Publication Number Publication Date
AR074504A1 true AR074504A1 (es) 2011-01-19

Family

ID=40852521

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP090104736A AR074504A1 (es) 2008-12-08 2009-12-07 Nucleotidos uracil ciclopropilicos

Country Status (21)

Country Link
US (1) US8399429B2 (es)
EP (1) EP2373671B1 (es)
JP (1) JP5683480B2 (es)
KR (1) KR20110104000A (es)
CN (1) CN102256991B (es)
AP (1) AP2011005717A0 (es)
AR (1) AR074504A1 (es)
AU (1) AU2009326125B2 (es)
BR (1) BRPI0922681A2 (es)
CA (1) CA2745523C (es)
CL (1) CL2011001364A1 (es)
EA (1) EA020244B1 (es)
ES (1) ES2525007T3 (es)
IL (1) IL212897A (es)
MX (1) MX2011006023A (es)
PA (1) PA8852101A1 (es)
SG (1) SG171973A1 (es)
TW (1) TW201036989A (es)
UY (1) UY32308A (es)
WO (1) WO2010066699A1 (es)
ZA (1) ZA201104231B (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3027B1 (ar) * 2009-05-14 2016-09-05 Janssen Products Lp نيوكليوسيدات يوراسيل سبيرواوكسيتان
CA2871547C (en) 2012-05-25 2021-05-25 Janssen R&D Ireland Uracyl spirooxetane nucleosides
AU2013346515B2 (en) * 2012-11-16 2017-05-25 NuCana plc Process for preparing nucleoside prodrugs
EP2940031B1 (en) * 2013-03-08 2017-09-27 Nanjing Sanhome Pharmaceutical Co., Ltd. Nucleoside phosphoramidate compounds for use in the treatment of hcv
CN103848876B (zh) * 2013-03-25 2016-05-11 安徽贝克联合制药有限公司 一种核苷磷酰胺前药及其制备方法和其应用
CN105377868A (zh) 2013-04-12 2016-03-02 艾其林医药公司 用于治疗hcv的高活性核苷衍生物
CN105348342B (zh) * 2014-09-30 2018-09-21 南京正大天晴制药有限公司 核苷氨基磷酸酯化合物及药物组合物和用途
WO2016073756A1 (en) * 2014-11-06 2016-05-12 Enanta Pharmaceuticals, Inc. Deuterated nucleoside/tide derivatives
CN105801646B (zh) * 2014-12-31 2019-08-16 浙江大德药业集团有限公司 炔基取代的核苷氨基磷酸酯
WO2016134053A1 (en) * 2015-02-18 2016-08-25 Abbvie Inc. Anti-viral compounds
EP3265102A4 (en) 2015-03-06 2018-12-05 ATEA Pharmaceuticals, Inc. Beta-d-2'-deoxy-2'alpha-fluoro-2'-beta-c-substituted-2-modified-n6-substituted purine nucleotides for hcv treatment
JP6743135B2 (ja) 2015-09-02 2020-08-19 アッヴィ・インコーポレイテッド 抗ウィルス性テトラヒドロフラン誘導体
LU100724B1 (en) 2016-07-14 2018-07-31 Atea Pharmaceuticals Inc Beta-d-2'-deoxy-2'-alpha-fluoro-2'-beta-c-substituted-4'-fluoro-n6-substituted-6-amino-2-substituted purine nucleotides for the treatment of hepatitis c virus infection
MY197236A (en) 2016-09-07 2023-06-07 Atea Pharmaceuticals Inc 2'-substituted-n6-substituted purine nucleotides for rna virus treatment
SG10202012214WA (en) 2017-02-01 2021-01-28 Atea Pharmaceuticals Inc Nucleotide hemi-sulfate salt for the treatment of hepatitis c virus
CN112351799A (zh) 2018-04-10 2021-02-09 阿堤亚制药公司 具有硬化的hcv感染患者的治疗
US10874687B1 (en) 2020-02-27 2020-12-29 Atea Pharmaceuticals, Inc. Highly active compounds against COVID-19

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4916122A (en) * 1987-01-28 1990-04-10 University Of Georgia Research Foundation, Inc. 3'-Azido-2',3'-dideoxyuridine anti-retroviral composition
DE69332616T2 (de) 1992-12-29 2003-11-06 Abbott Lab Hemmer der retroviralen Protease
US20010021509A1 (en) * 1997-10-23 2001-09-13 Sathe Ganesh Madhusudan cDNA clone HNEAA81 that encodes a human 7-transmembrane receptor
CN103319554A (zh) * 2002-06-28 2013-09-25 埃迪尼克斯医药公司 用于治疗黄病毒感染的修饰的2’和3’-核苷前药
EP2298783B1 (en) * 2003-02-19 2017-12-06 Yale University Anti-viral nucleoside analogs and methods for treating viral infections, especially hiv infections
EP1628685B1 (en) * 2003-04-25 2010-12-08 Gilead Sciences, Inc. Antiviral phosphonate analogs
JP2008532950A (ja) * 2005-03-08 2008-08-21 バイオタ サイエンティフィック マネージメント ピーティーワイ リミテッド 治療薬としての二環式ヌクレオシドおよび二環式ヌクレオチド
ATE493428T1 (de) 2006-10-10 2011-01-15 Medivir Ab Hcv-nukleosidinhibitor

Also Published As

Publication number Publication date
EA020244B1 (ru) 2014-09-30
MX2011006023A (es) 2011-06-28
US8399429B2 (en) 2013-03-19
IL212897A (en) 2013-12-31
JP2012510980A (ja) 2012-05-17
CA2745523C (en) 2017-07-04
CN102256991B (zh) 2015-08-12
EA201170780A1 (ru) 2011-12-30
TW201036989A (en) 2010-10-16
SG171973A1 (en) 2011-07-28
CA2745523A1 (en) 2010-06-17
CL2011001364A1 (es) 2011-09-23
UY32308A (es) 2010-06-30
US20110230436A1 (en) 2011-09-22
PA8852101A1 (es) 2010-07-27
ZA201104231B (en) 2012-11-28
AP2011005717A0 (en) 2011-06-30
IL212897A0 (en) 2011-07-31
JP5683480B2 (ja) 2015-03-11
WO2010066699A1 (en) 2010-06-17
EP2373671B1 (en) 2014-09-10
BRPI0922681A2 (pt) 2016-01-05
AU2009326125B2 (en) 2015-03-12
ES2525007T3 (es) 2014-12-17
CN102256991A (zh) 2011-11-23
EP2373671A1 (en) 2011-10-12
KR20110104000A (ko) 2011-09-21
AU2009326125A1 (en) 2010-06-17

Similar Documents

Publication Publication Date Title
AR074504A1 (es) Nucleotidos uracil ciclopropilicos
AR076579A1 (es) Espironucleosidos uracilicos oxetanicos, composiciones farmaceuticas que los contienen y uso de los mismos como inhibidores del virus de la hepatitis c (vhc).
AR072428A1 (es) Derivados de pirimidin nucleotidos inhibidores de polimerasas del virus de la hepatitis c (vhc), composiciones farmaceuticas que los contienen y metodo para prepararlos.
AR092269A1 (es) Sulfamoilarilamidas y su uso como medicamentos para el tratamiento de la hepatitis b
AR077695A1 (es) Derivados de pirimidina como inhibidores del factor ixa
AR067757A1 (es) Derivados de imidazo[4,5-c]piridin-2-ona, composiciones farmaceuticas que los contienen, procedimiento para su preparacion y uso de los mismos como agentes antivirales.
CO6251260A2 (es) Derivados de bifenilo conformacionalmente restringido para uso como inhibidores del virus de la hepatitis c.
AR053120A1 (es) Aminopiridinas como inhibidores de beta secretasa
ES2600636T3 (es) Spiro-[1,3]-oxazinas y spiro-[1,4]-oxazepinas como inhibidores de BACE1 y/o BACE2
CO6230986A2 (es) Compuesto de 4-piridinona y su uso para cancer
AR083760A1 (es) Agentes antibacterianos y composiciones farmaceuticas
AR082619A1 (es) Inhibidores del virus de la hepatitis c
AR059621A1 (es) Acidos 4- fenil- tiazol-5- carboxilicos y amidas de acidos 4- fenil- tiazol5 carboxilicos como inhibidores de la plk1
EA201600241A1 (ru) Замещенные (2r,3r,5r)-3-гидрокси-(5-пиримидин-1-ил)тетрагидрофуран-2-илметил арил фосфорамидаты
AR082968A1 (es) Inhibidores biciclicos de notum pectinacetilesterasa y una composicion farmaceutica en base al compuesto
ES2479718T3 (es) Nuevos derivados de tetrahidroquinolina
AR088414A1 (es) Derivados sustituidos de indol
AR073037A1 (es) Derivados de enfumafungina, utiles en la inhibicionde (1,3)-beta-d-glucano sintasa
AR100126A1 (es) Activadores de herg policíclicos
AR080102A1 (es) Compuestos de aril-bencil-amina y su utilizacion en el tratamiento de trastornos mediados por las interacciones de los linfocitos
PE20061012A1 (es) Derivados piperidinil piperazina como inhibidores de receptores quiomicina
AR112803A2 (es) Derivados de piperazina como moduladores de piruvato quinasa m2 (pkm2)
AR079265A1 (es) Derivados de azabiciclo(3.1.0)hex-2-ilo, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen
TH112183B (th) สารยับยั้งไซโคลโพรพิล พอลิเมอเรส
AR082224A1 (es) Derivados fosforamidato de nucleosidos de guanina, composiciones farmaceuticas que los contienen y uso de los mismos para tratar infecciones virales, en particular infecciones por vhc

Legal Events

Date Code Title Description
FA Abandonment or withdrawal